[go: up one dir, main page]

EP0158684A1 - Hemoglobin-based blood gas control - Google Patents

Hemoglobin-based blood gas control Download PDF

Info

Publication number
EP0158684A1
EP0158684A1 EP84104274A EP84104274A EP0158684A1 EP 0158684 A1 EP0158684 A1 EP 0158684A1 EP 84104274 A EP84104274 A EP 84104274A EP 84104274 A EP84104274 A EP 84104274A EP 0158684 A1 EP0158684 A1 EP 0158684A1
Authority
EP
European Patent Office
Prior art keywords
liquid
present
concentration
nadh
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP84104274A
Other languages
German (de)
French (fr)
Other versions
EP0158684B1 (en
Inventor
Chiang Ching
Susan K. Bolton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cessione iniziative Marittime 1991 Srl
Original Assignee
Allied Corp
Fisher Scientific Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US06/427,470 priority Critical patent/US4485174A/en
Application filed by Allied Corp, Fisher Scientific Co LLC filed Critical Allied Corp
Priority to EP84104274A priority patent/EP0158684B1/en
Priority to DE8484104274T priority patent/DE3476462D1/en
Priority to JP59088230A priority patent/JPS60231166A/en
Publication of EP0158684A1 publication Critical patent/EP0158684A1/en
Application granted granted Critical
Publication of EP0158684B1 publication Critical patent/EP0158684B1/en
Expired legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G01N2333/805—Haemoglobins; Myoglobins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/70—Blood gas control solutios containing dissolved oxygen, bicarbonate and the like
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/102499—Blood gas standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Definitions

  • This invention relates to control liquids for quality control and/or calibration of equipment for the analysis of blood gas and the like.
  • Blood gas analyzers are utilized to measure parameters of blood such as pH, partial pressure of carbon dioxide (expressed as pC0 2 ), and partial pressure of oxygen (expressed as p02).
  • Such blood ga ' s analyzers require frequent calibration and quality control checks to ensure that the analyzer is operating properly and accurately. In connection with such quality control and calibration procedures, it is convenient to use a prepared control liquid of constant, known composition to monitor the accuracy of such analyzers.
  • control liquids should contain a component which can reversibly bind oxygen.
  • this component can be either an artificial or a blood-derived material.
  • hemoglobin-based blood gas control liquids The usefulness of hemoglobin-based blood gas control liquids is limited by the autoxidation of the hemoglobin molecule to methemoglobin, which cannot reversibly bind oxygen.
  • methemoglobin content increases, the oxyhemoglobin dissociation curve shifts to the left with an apparent fading of the sigmoid- shaped inflection to a hyperbolic curve; thus, the liquid's utility as a blood gas control is compromised.
  • Stable methemoglobin values in such liquids are also important when the liquid is used to calibrate the various hemoglobin channels of an analyzer such as the Instrumentation Laboratory. "CO-OXIMETER" analyzer.
  • the methemoglobin level in a hemoglobin-based control liquid can be controlled by the addition to the liquid of a reduced pyridine nucleotide or by the addition of a system for generating a reduced pyridine nucleotide, and that this addition does not adversely affect the other blood gas control functions of the liquid.
  • NADH and NADPH are the preferred reduced nucleotides, and NA D H, being more effective than NADPH, is most preferred.
  • a generating system including one or more substrates and one or more enzymes reactive with the substates, is preferred over the simple addition of NADH or NADPH because a generating system provides a longer-lasting capacity to control the methemoglobin level, NADH or NADPH molecules being replenished by the system as other molecules are oxidized.
  • Suitable pyridine nucleotides which can be used to generate suitable reduced nucleotides are the following NAD analogs: 3-acetylpyridine-adenine dinucleotide (3-AP-NAD); 3-pyridinealdehyde-adenine dinucleotide (3-PA-NAD) thionicotinamide-adenine dinucleotide (Thio-NAD): nicotinamide-hypoxanthine dinucleotide (Deamino-NAD); 3-acetylpyridine- hypoxanthine dinucleotide (3-AP-Deam-NAD); and 3-pyridinealdehyde-hypoxanthine dinucleotide (3-PA-Deam-NAD).
  • NAD analogs 3-acetylpyridine-adenine dinucleotide (3-AP-NAD); 3-pyridinealdehyde-adenine dinucleotide (3-PA-NAD) thionico
  • the hemoglobin-based control liquid of the invention can be further improved by the addition of an organic phosphate capable of increasing and stabilizing the oxygen buffering capacity (P 50 ) of the liquid, preferably to the level found in normal blood, about 27 mm Hg.
  • the preferred organic phosphate is inositol hexaphosphate (IHP), which provides the further advantage of enhancing the reduction of methemoglobin to normal hemoglobin.
  • Suitable organic phosphates are adenosine triphosphate, adenosine disphosphate, adenosine monophosphate, guanidine triphosphate, guanidine monophosphate, 2, 3-diphosphoglycerate, ribose-5-phosphate, and pyridoxine-5-phosphate.
  • Suitable inorganic phosphates are pyrophosphate, tripolyphosphate, tetrametaphosphate, and hexametaphosphate.
  • the liquid contain an active methemoglobin reductase, an enzyme which can employ NADH and NADPH as electron donors and which is involved in a mechanism by which NADH and NADPH reduce methemoglobin to normal hemoglobin in mammalian blood.
  • Methemoglobin reductases are naturally present in red blood cell hemolysate, and additional enzyme can be obtained from a biochemical supply company such as CalBiochem-Behring, LaJolla, CA, and can be added to the blood gas control liquid as needed for maintenance of the desired methemoglobin level.
  • the action of methemoglobin reductase is enhanced by the presence of the aforementioned organic and inorganic phosphates.
  • the blood gas control liquid of the inveption contains, in addition to hemoglobin and the reduced pyridine nucleotide or generating system therefor, at least one pH buffering agent.
  • the liquid can also contain a base for raising the pH of the liquid to between about 7.0 and 8.0, and a preservative in a concentration sufficient to inhibit microbiol growth without impairing quality control functions.
  • the preferred preservative is 2-phenoxyethanol.
  • the liquid is preferably supplied enclosed in gas-tight, sealed ampuls, and contains known concentrations of carbon dioxide and oxygen.
  • a number of enzyme systems are known which are capable of generating NADH or NADPH and which are suitable for use in the blood gas control liquid of the invention. Suitable systems are listed under the heading "Uxidoreductases" in the Enzyme Commission Table of Enzymes. In the systems listed therein, NAD and NA D P act as proton acceptors and thus are converted to the desired reduced compounds NADH or NA D PH.
  • the use of NADH as an electron donor for methemoglobin reductase, which reduces methemoglobin, may shift the equilibrium toward the right in the hemoglobin-based blood gas control.
  • the reaction rate can be controlled by adjusting the relative concentrations of the reactants on the left side of the equation, to continuously provide the desired amount of NADH.
  • Hemolysate the preferred source of hemoglobin, contains L-lactic acid, LDH, and methemoglobin reductase, making it in some cases unnecessary to add much, if any, of these components when hemolysate is used. If commercially available powdered hemoglobin is used, however, these components must be provided from commercial sources.
  • a preservative should be present in a concentration of at least 0.2%, and most preferably at least 0.4%, by volume, to ensure that no microbiol growth occurs.
  • the most preferred preservative is 2-phenoxyethanol.
  • Other suitable preservatives are those containing 6-acetoxy-2, 4-dimethyl-m-dioxane; o-phenylphenol, 2-[(hydroxymethyl)amino]-2 methylpropanol; alkyl-p-hydroxybenzoate; o-phenlphenate (sodium-o-phenyl-phenate tetrahydrate); 2-[hydroxymethyl]amino]ethanol; 3,5-dimethyl-trihyaro-1,3,5-2H-thiadiazine-2-thione; l,2-dibromo-2,4-dicyanobutane; or benzyl bromoacetate.
  • Antibiotics such as gentamycin sulfate or polymyxin B can be used, but at greater expense. Alternatively, microbiol
  • the blood gas control liquids are preferably formulated to similate three physiological levels of pH, pCO 2 , and p02 values.
  • the choice of buffer used in the control liquids of the invention depends in part on whether the liquid is to be used for normal, acidosis, or alkalosis control.
  • the buffer for the normal control should have a pKa appropriate for the optimal pH, 7.4, of that liquid.
  • TAPSO one of the Good buffers, named after their discoverer
  • the chemical name of TAPSO is 3-[N-tris-hydroxymethyl) methyl amino]-2-hydroxypropane sulfonic acid.
  • TES N-tris(hydroxymethyl)-methyl-2- aminoethane sulfonic acid
  • p K a 7.50
  • BES N, N-bis-(2-Hydroxyethyl)-2-aminoethane sulfonic acid
  • DIPSO DIPSO
  • HEPES N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid
  • PKa 7.55
  • HEPPSO N-hydroxyethylpiperazine-N-2-hydroxypropane sulfonic acid
  • MOPS 3-(N-Morpholino)-propane sulfonic acid
  • Final buffer concentrations will normally range between 0.05 M and 0.15 M.
  • a normal blood gas control liquid is made as follows. First, hemolysate is prepared by centrifuging human heparinized whole blood, at 4°C, at 270 g for 15 minutes to remove the plasma. Blood in ACD or CPDA solutions can also be used. The red blood cells are then washed twice with cold 0.9% NaCl and then lysed with 0.1 M-0.15 M TAPSO, pH 8. The volumetric proportion of buffer to red blood cells is between 1:3 and 1:1, depending on the level of hemoglobin desired in the final product. Generally, the hemoglobin concentration is lowest for the acidosis control, higher for the normal control, and highest for the alkalosis control.
  • Total hemoglobin concentration ranges typically are: acidosis: 8-10 g/dL; normal: 14-16 g/dL; alkalosis: 18-20 g/dL.
  • the hemoglobin level in a sample can be lowered to a' desired level by diluting the sample with buffer.
  • the hemolysate is then extracted with one-quarter volume of toluene and allowed to sit overnight at 4°C.
  • the separated hemolysate is then centrifuged at 1,500 g for 30 minutes to remove any remaining cellular debris, and then at 30,000 g for 90 minutes to remove traces of stroma.
  • the pH is adjusted as desired with dilute NaOH.
  • L-lactic acid, LDH, and methemoglobin reductase are normally present endogenously in hemolysate, in many cases only NAD and IHP need be added in order to maintain low methemoglobin levels for several months. Additional LDH and methemoglobin reductase are added, if necessary, to give concentrations of between five and fifteen, most preferably 7, units per ml of liquid. L-lactic can also be added, if necessary, to give a concentration between 0.02 M and 0.06 M. Lactic acid is added in a neutralized, concentrated buffer solution along with NAD and IHP.
  • LDH is available from Boehringer Mannheim Biochemicals, Indianapolis, IN, and lactic acid is available from Sigma Chemical Co., St. Louis, MO.
  • NAD is added to give a concentration between 0.14 mM and 1.4 mM, most preferably 0.7 mM, (0.1 to 1 mg/ml liquid) and IHP is added to give a concentration of between 1.0 mM and 1.6 mM, most preferably 1.4 mM.
  • Final adjustment of pH is then carried out by the addition of dilute (1 N) NaOH. This sometimes results in the formation of a precipitate, which is removed by centrifugation at 1,500 g for 30 minutes, or by filtration. If desired, membrane sterilization is then carried out using sterile 0.22 M filters attached to syringes.
  • the P 50 i.e., the oxygen tension at which hemoglobin was 50% oxygenated, was measured in samples which were withdrawn after tonometry in an Instrumentation Laboratory Model 237 Tonometer with a gas mixture of 5.1% C0 2 /2.8% 0 2 , and which were found to have oxyhemoglobin values of 40% to 60%.
  • curve A represents the sample just described
  • curve B represents a sample prepared as just described and having in addition a small amount of the preservative 2-phenoxyethanol
  • curve C represents a sample as just described except that a greater amount of IHP is added
  • curve D represents hemolysate containing no additives
  • curves A and B come very close to the ideal P 50 of 27. Tests performed to determine the stability of the P 50 indicated that, for samples represented by curve A in the Figure, the P 50 after 7 months was approximately 28, while that for the curve C samples was about 30.5.
  • Improved pH control is provided in the liquids of the invention by the addition of NaHCO 3 during tonometry.
  • concentration of NaHCO 3 as well as the percentage of 0 2 and C0 2 , varies, depending on whether the liquid is normal, alkalosis, or acidosis. Below are approximate preferred values. i

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Blood gas control containing hemoglobin, a pH buffering agent, and a reduced pyridine nucleotide capable of participating in a reaction which reduces methemoglobin to normal hemoglobin.

Description

    Background of the Invention
  • This invention relates to control liquids for quality control and/or calibration of equipment for the analysis of blood gas and the like.
  • Blood gas analyzers are utilized to measure parameters of blood such as pH, partial pressure of carbon dioxide (expressed as pC02), and partial pressure of oxygen (expressed as p02). Such blood ga's analyzers require frequent calibration and quality control checks to ensure that the analyzer is operating properly and accurately. In connection with such quality control and calibration procedures, it is convenient to use a prepared control liquid of constant, known composition to monitor the accuracy of such analyzers.
  • Such control liquids should contain a component which can reversibly bind oxygen. Generally, this component can be either an artificial or a blood-derived material.
  • The usefulness of hemoglobin-based blood gas control liquids is limited by the autoxidation of the hemoglobin molecule to methemoglobin, which cannot reversibly bind oxygen. When the methemoglobin content increases, the oxyhemoglobin dissociation curve shifts to the left with an apparent fading of the sigmoid- shaped inflection to a hyperbolic curve; thus, the liquid's utility as a blood gas control is compromised. Stable methemoglobin values in such liquids are also important when the liquid is used to calibrate the various hemoglobin channels of an analyzer such as the Instrumentation Laboratory. "CO-OXIMETER" analyzer.
  • We have discovered that the methemoglobin level in a hemoglobin-based control liquid can be controlled by the addition to the liquid of a reduced pyridine nucleotide or by the addition of a system for generating a reduced pyridine nucleotide, and that this addition does not adversely affect the other blood gas control functions of the liquid. NADH and NADPH are the preferred reduced nucleotides, and NADH, being more effective than NADPH, is most preferred. The addition of a generating system, including one or more substrates and one or more enzymes reactive with the substates, is preferred over the simple addition of NADH or NADPH because a generating system provides a longer-lasting capacity to control the methemoglobin level, NADH or NADPH molecules being replenished by the system as other molecules are oxidized.
  • Other suitable pyridine nucleotides which can be used to generate suitable reduced nucleotides are the following NAD analogs: 3-acetylpyridine-adenine dinucleotide (3-AP-NAD); 3-pyridinealdehyde-adenine dinucleotide (3-PA-NAD) thionicotinamide-adenine dinucleotide (Thio-NAD): nicotinamide-hypoxanthine dinucleotide (Deamino-NAD); 3-acetylpyridine- hypoxanthine dinucleotide (3-AP-Deam-NAD); and 3-pyridinealdehyde-hypoxanthine dinucleotide (3-PA-Deam-NAD).
  • These are available commercially but are less preferred than an NADH generating system because of their comparatively greater expense.
  • The hemoglobin-based control liquid of the invention can be further improved by the addition of an organic phosphate capable of increasing and stabilizing the oxygen buffering capacity (P50) of the liquid, preferably to the level found in normal blood, about 27 mm Hg. The preferred organic phosphate is inositol hexaphosphate (IHP), which provides the further advantage of enhancing the reduction of methemoglobin to normal hemoglobin.
  • Other suitable organic phosphates are adenosine triphosphate, adenosine disphosphate, adenosine monophosphate, guanidine triphosphate, guanidine monophosphate, 2, 3-diphosphoglycerate, ribose-5-phosphate, and pyridoxine-5-phosphate. Suitable inorganic phosphates are pyrophosphate, tripolyphosphate, tetrametaphosphate, and hexametaphosphate.
  • In control liquds of the invention which employ NADH or NADPH it is preferred that the liquid contain an active methemoglobin reductase, an enzyme which can employ NADH and NADPH as electron donors and which is involved in a mechanism by which NADH and NADPH reduce methemoglobin to normal hemoglobin in mammalian blood. Methemoglobin reductases are naturally present in red blood cell hemolysate, and additional enzyme can be obtained from a biochemical supply company such as CalBiochem-Behring, LaJolla, CA, and can be added to the blood gas control liquid as needed for maintenance of the desired methemoglobin level. The action of methemoglobin reductase is enhanced by the presence of the aforementioned organic and inorganic phosphates.
  • The blood gas control liquid of the inveption contains, in addition to hemoglobin and the reduced pyridine nucleotide or generating system therefor, at least one pH buffering agent. The liquid can also contain a base for raising the pH of the liquid to between about 7.0 and 8.0, and a preservative in a concentration sufficient to inhibit microbiol growth without impairing quality control functions. The preferred preservative is 2-phenoxyethanol. The liquid is preferably supplied enclosed in gas-tight, sealed ampuls, and contains known concentrations of carbon dioxide and oxygen.
  • A number of enzyme systems are known which are capable of generating NADH or NADPH and which are suitable for use in the blood gas control liquid of the invention. Suitable systems are listed under the heading "Uxidoreductases" in the Enzyme Commission Table of Enzymes. In the systems listed therein, NAD and NADP act as proton acceptors and thus are converted to the desired reduced compounds NADH or NADPH.
  • The NADH-generating system we currently prefer is illustrated below:
    • L-lactic acid + NAD Lactate dehydrogenase (LDH) Pyruvic acid + NADH
  • Although the theoretically favored direction of the above reaction is right to left, the use of NADH as an electron donor for methemoglobin reductase, which reduces methemoglobin, may shift the equilibrium toward the right in the hemoglobin-based blood gas control. The reaction rate can be controlled by adjusting the relative concentrations of the reactants on the left side of the equation, to continuously provide the desired amount of NADH. Levels of NAD higher than about 1.0 mg NAD per ml liquid, however, are not desirable because such levels can cause an undesirable decrease in pH over time; about 0.5 to 1.0 mg NAD per ml liquid is therefore preferred.
  • Hemolysate, the preferred source of hemoglobin, contains L-lactic acid, LDH, and methemoglobin reductase, making it in some cases unnecessary to add much, if any, of these components when hemolysate is used. If commercially available powdered hemoglobin is used, however, these components must be provided from commercial sources.
  • A preservative should be present in a concentration of at least 0.2%, and most preferably at least 0.4%, by volume, to ensure that no microbiol growth occurs. The most preferred preservative is 2-phenoxyethanol. Other suitable preservatives are those containing 6-acetoxy-2, 4-dimethyl-m-dioxane; o-phenylphenol, 2-[(hydroxymethyl)amino]-2 methylpropanol; alkyl-p-hydroxybenzoate; o-phenlphenate (sodium-o-phenyl-phenate tetrahydrate); 2-[hydroxymethyl]amino]ethanol; 3,5-dimethyl-trihyaro-1,3,5-2H-thiadiazine-2-thione; l,2-dibromo-2,4-dicyanobutane; or benzyl bromoacetate. Antibiotics, such as gentamycin sulfate or polymyxin B can be used, but at greater expense. Alternatively, microbiol growth can be inhibited by employing fine-filter membrane sterilization.
  • The blood gas control liquids are preferably formulated to similate three physiological levels of pH, pCO2, and p02 values. The choice of buffer used in the control liquids of the invention depends in part on whether the liquid is to be used for normal, acidosis, or alkalosis control. The buffer for the normal control should have a pKa appropriate for the optimal pH, 7.4, of that liquid. TAPSO (one of the Good buffers, named after their discoverer) is preferred for the normal control because its pKa = 7.39 (at 37°C). The chemical name of TAPSO is 3-[N-tris-hydroxymethyl) methyl amino]-2-hydroxypropane sulfonic acid. Buffers having different pKa values may be more appropriate for acidosis and alkalosis controls; e.g. TES (N-tris(hydroxymethyl)-methyl-2- aminoethane sulfonic acid; pKa = 7.50) and BES (N, N-bis-(2-Hydroxyethyl)-2-aminoethane sulfonic acid; pKa= 7.15) may be used, respectively, in those liquids. Other buffers having pKa values between 7 and 8 are DIPSO (3-[N-bis-(hydroxyethyl)-amino]-2-hydroxypropane sulfonic acid; pKa = 7.35); HEPES (N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid; PKa = 7.55); HEPPSO (N-hydroxyethylpiperazine-N-2-hydroxypropane sulfonic acid; pKa = 7.73); MOPS (3-(N-Morpholino)-propane sulfonic acid; pKa = 7.20); and POPSO (Piperazine-N,N'-bis-(2-hydroxypropane sulfonic acid; pKa = 7.63). Final buffer concentrations will normally range between 0.05 M and 0.15 M.
  • Other features and advantages of the invention will be seen as the following description of a particular embodiment progresses, in connection with the drawing, in which:
    • The FIGURE is a graph of the relation Between oxygen tension and percent oxyhemoglobin in five hemoglobin-containing liquid samples.
    Description of Particular Embodiment
  • A normal blood gas control liquid is made as follows. First, hemolysate is prepared by centrifuging human heparinized whole blood, at 4°C, at 270 g for 15 minutes to remove the plasma. Blood in ACD or CPDA solutions can also be used. The red blood cells are then washed twice with cold 0.9% NaCl and then lysed with 0.1 M-0.15 M TAPSO, pH 8. The volumetric proportion of buffer to red blood cells is between 1:3 and 1:1, depending on the level of hemoglobin desired in the final product. Generally, the hemoglobin concentration is lowest for the acidosis control, higher for the normal control, and highest for the alkalosis control. Total hemoglobin concentration ranges typically are: acidosis: 8-10 g/dL; normal: 14-16 g/dL; alkalosis: 18-20 g/dL. The hemoglobin level in a sample can be lowered to a' desired level by diluting the sample with buffer. The hemolysate is then extracted with one-quarter volume of toluene and allowed to sit overnight at 4°C. The separated hemolysate is then centrifuged at 1,500 g for 30 minutes to remove any remaining cellular debris, and then at 30,000 g for 90 minutes to remove traces of stroma. The pH is adjusted as desired with dilute NaOH.
  • The desired additives are then mixed into the hemoglobin samples. Because L-lactic acid, LDH, and methemoglobin reductase are normally present endogenously in hemolysate, in many cases only NAD and IHP need be added in order to maintain low methemoglobin levels for several months. Additional LDH and methemoglobin reductase are added, if necessary, to give concentrations of between five and fifteen, most preferably 7, units per ml of liquid. L-lactic can also be added, if necessary, to give a concentration between 0.02 M and 0.06 M. Lactic acid is added in a neutralized, concentrated buffer solution along with NAD and IHP. LDH is available from Boehringer Mannheim Biochemicals, Indianapolis, IN, and lactic acid is available from Sigma Chemical Co., St. Louis, MO. NAD is added to give a concentration between 0.14 mM and 1.4 mM, most preferably 0.7 mM, (0.1 to 1 mg/ml liquid) and IHP is added to give a concentration of between 1.0 mM and 1.6 mM, most preferably 1.4 mM. Final adjustment of pH is then carried out by the addition of dilute (1 N) NaOH. This sometimes results in the formation of a precipitate, which is removed by centrifugation at 1,500 g for 30 minutes, or by filtration. If desired, membrane sterilization is then carried out using sterile 0.22 M filters attached to syringes.
  • The P50, i.e., the oxygen tension at which hemoglobin was 50% oxygenated, was measured in samples which were withdrawn after tonometry in an Instrumentation Laboratory Model 237 Tonometer with a gas mixture of 5.1% C02/2.8% 02, and which were found to have oxyhemoglobin values of 40% to 60%. The results are shown in the Figure, in which curve A represents the sample just described; curve B represents a sample prepared as just described and having in addition a small amount of the preservative 2-phenoxyethanol; curve C represents a sample as just described except that a greater amount of IHP is added; curve D represents hemolysate containing no additives; and curve E represents whole blood, having an ideal P50=27. As is shown in the Figure, curves A and B come very close to the ideal P50 of 27. Tests performed to determine the stability of the P50 indicated that, for samples represented by curve A in the Figure, the P50 after 7 months was approximately 28, while that for the curve C samples was about 30.5.
  • Improved pH control is provided in the liquids of the invention by the addition of NaHCO3 during tonometry. The concentration of NaHCO3, as well as the percentage of 02 and C02, varies, depending on whether the liquid is normal, alkalosis, or acidosis. Below are approximate preferred values. i
    Figure imgb0001
  • While a particular embodiment of the invention has been shown and described, various modifications will be apparent to those skilled in the art. Therefore it is not intended that the invention be limited to the disclosed embodiment or to details thereof and departures may be made therefrom within the spirit and scope of the invention.

Claims (10)

1. A control liquid for a blood gas analyzer or the like comprising
hemoglobin,
a pH buffering agent, and
a reduced pyridine nucleotide capable of participating in a reaction which reduces methemoglobin to normal hemoglobin.
2. The control liquid of claim 1 and further including methemoglobin reductase and wherein said reduced pyridine nucleotide is NADPH or NADH.
3. The control liquid of claim 2 wherein said NADH or NADPH is provided by an NADH or NADPH generating system comprising one or more substrates and one or more enzymes reactive with said one or more substrates to generate sufficient NADH or NADPH to control the level of said methemoglobin in said control liquid.
4. The control liquid of claim 3 wherein said NADH or NADPH generating system is an NADH generating system comprising the chemical components L-lactic acid, NAD, and lactate dehydrogenase (LDH), said chemical components being present in amounts and proportions sufficient to generate said NADH according to the following reaction:
L-lactic acid + NAD
Figure imgb0002
pyruvic acid + NADH.
5. The control liquid of claim 1, said liquid being provided in a sealed container, said control liquid having a pH in the range of 7.0 to 8.0, carbon dioxide in the range of 7% and oxygen in the range of 2-12%. __
6. The control liquid of claim 1 further comprising a preservative present in a concentration sufficient to inhibit microbial growth in said liquid without impairing the quality control functions of said liquid.
7. The control liquid of claim 4, wherein said hemoglobin is provided as a component of a mammalian erythrocyte hemolysate which also contains said methemoglobin reductase, said hemolysate and said pH buffering agent being present in the respective proportions of between 1:1 and 3:1, by volume,
said NAD is present in the concentration of between 0.1 mg and 1.0 mg per ml of liquid,
said methemoglobin reductase is present in the concentration of between five and fifteen units per ml of liquid,
said LDH is present in the concentration of between five and fifteen units per ml of liquid,
said L-lactic acid is present in the concentration of between 0.02 M and 0.06 M, and
said pH buffering agent is TAPSO, BES, or TES in a concentration of between 0.05 M and 0.15 M.
8. The control liquid of claim 7, further comprising an organic phosphate capable of increasing and stabilizing the P50 of said liquid, and a preservative present in a concentration sufficient to inhibit microbial growth in said liquid without impairing the quality control functions of said liquid.
9. The control liquid of claim 8 wherein
said hemolysate and said pH buffering agent are present in the respective proportions of 1:1, by volume,
said LDH is present in the concentration of 7 units per ml of liquid,
said L-lactic acid is present in the concentration of 0.04 M,
said methemoglobin reductase is present in the concentration of 7 units per ml of liquid,
said inositol hexaphosphate is present in the concentration of 1.4 mM,
said NAD is present in the concentration of 0.5 mg per ml of liquid, and
said 2-phenoxyethanol is present in the concentration of 0.4%, by volume.
10. The control liquid of any one of claims 1, 4 or 9 wherein said liquid is in a sealed container and has a hemoglobin content in the range of 6-22 g/dL, a pH in the range of 7.0 to 8.0, a carbon dioxide content in the range of 1-7%, and an oxygen content in the range of 2-12%.
EP84104274A 1982-09-29 1984-04-16 Hemoglobin-based blood gas control Expired EP0158684B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US06/427,470 US4485174A (en) 1982-09-29 1982-09-29 Hemoglobin-based blood gas control
EP84104274A EP0158684B1 (en) 1982-09-29 1984-04-16 Hemoglobin-based blood gas control
DE8484104274T DE3476462D1 (en) 1984-04-16 1984-04-16 Hemoglobin-based blood gas control
JP59088230A JPS60231166A (en) 1982-09-29 1984-05-01 Hemoglobin-based blood gas control fluid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/427,470 US4485174A (en) 1982-09-29 1982-09-29 Hemoglobin-based blood gas control
EP84104274A EP0158684B1 (en) 1982-09-29 1984-04-16 Hemoglobin-based blood gas control

Publications (2)

Publication Number Publication Date
EP0158684A1 true EP0158684A1 (en) 1985-10-23
EP0158684B1 EP0158684B1 (en) 1989-01-25

Family

ID=26091634

Family Applications (1)

Application Number Title Priority Date Filing Date
EP84104274A Expired EP0158684B1 (en) 1982-09-29 1984-04-16 Hemoglobin-based blood gas control

Country Status (3)

Country Link
US (1) US4485174A (en)
EP (1) EP0158684B1 (en)
JP (1) JPS60231166A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0185404A1 (en) * 1984-11-09 1986-06-25 Euro-Trol B.V. Stroma-free hemoglobin solution, process for the preparation thereof and its application
EP0615747A1 (en) * 1993-03-18 1994-09-21 Terumo Kabushiki Kaisha Hemoglobin-encapsulating liposome and method for making the same
US5674528A (en) * 1994-06-15 1997-10-07 Terumo Kabushiki Kaisha Hemoglobin-encapsulated liposome

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3311458C2 (en) * 1983-03-29 1986-02-13 panchem GmbH, 8751 Kleinwallstadt Method for producing a glucose-free hemoglobin control
JPS6073356A (en) * 1983-09-29 1985-04-25 Toa Medical Electronics Co Ltd Reagent for blood analysis
US5281579A (en) * 1984-03-23 1994-01-25 Baxter International Inc. Purified virus-free hemoglobin solutions and method for making same
US4711852A (en) * 1984-11-05 1987-12-08 Akzo N.V. Control for blood gas analyzers and hemoglobin analysis
US4753888A (en) * 1986-04-09 1988-06-28 Bionostics, Inc. Multiple control standard for blood analysis
US5194590A (en) * 1986-06-20 1993-03-16 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5464814A (en) * 1986-06-20 1995-11-07 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5422278A (en) * 1987-11-17 1995-06-06 Dade International Inc. Blood gas/electrolyte calibrator and quality controls
US5045529A (en) * 1989-03-27 1991-09-03 Bionostics, Inc. Tonometric fluid for blood gas and co-oximetry instruments
US5558985A (en) * 1989-03-27 1996-09-24 Bionostics Incorporated Stable hemoglobin reference solution
US5246859A (en) * 1990-10-15 1993-09-21 Puritan-Bennett Corporation Method of stabilizing a carbon dioxide sensor
WO1992008130A1 (en) * 1990-10-26 1992-05-14 Diametrics Medical, Inc. Temperature insensitive calibration system
US5231030A (en) * 1990-10-26 1993-07-27 Diametrics Medical, Inc. Temperature insensitive calibration system
US5223433A (en) * 1991-12-13 1993-06-29 Diametrics Medical Inc. Temperature stabilized fluid calibration system
US5212092A (en) * 1992-05-22 1993-05-18 Puritan-Bennett Corporation Storage and calibration solution for multiparameter intravascular blood gas sensor device
RU2337705C2 (en) * 2003-01-29 2008-11-10 Нортфилд Лэборэтериз, Инк. Polymerised haemoglobin solutions with lowered tetramer content and method of production thereof
EP1978802A2 (en) * 2006-01-24 2008-10-15 Northfield Laboratories, Inc. Polymerized hemoglobin media and its use in isolation and transplantation of islet cells
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
AU2009243090C1 (en) 2008-04-30 2014-03-06 Instrumentation Laboratory Company Hemoglobin based bilirubin reference material
JP6817941B2 (en) * 2014-09-08 2021-01-20 インディアン インスティテゥート オブ サイエンスＩｎｄｉａｎ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｓｃｉｅｎｃｅ Devices and methods for detecting hemoglobin and complexes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3466249A (en) * 1967-02-13 1969-09-09 Baxter Laboratories Inc Blood serum reference standard for multi-automated analytical procedures
US4049673A (en) * 1971-06-08 1977-09-20 Israel Herbert Scheinberg Preparation of ferrous hemoglobin and enzymatic digestion products thereof active for absorption of carbon monoxide
US3859049A (en) * 1973-09-14 1975-01-07 Arnold G Ware Blood reference standard and process for blood gas test
US3962125A (en) * 1975-01-13 1976-06-08 Coulter Diagnostics, Inc. Multi-purpose diluent for use in blood analysis by electronic instrumentation of the coulter type
US4163734A (en) * 1975-05-30 1979-08-07 Radiometer A/S Reference liquid for blood gas equipment
US4001142A (en) * 1975-07-25 1977-01-04 Warner-Lambert Company Blood gas control
US3973913A (en) * 1976-01-29 1976-08-10 Louderback Allan Lee Blood control standard
US4112070A (en) * 1977-06-08 1978-09-05 Research Corporation Blood preservation system
US4126575A (en) * 1977-11-22 1978-11-21 Louderback Allan Lee Blood control standard
US4199471A (en) * 1978-11-16 1980-04-22 Louderback Allan Lee Freeze-stable liquid blood control standard
JPS55113750U (en) * 1979-02-05 1980-08-11
US4401122A (en) * 1979-08-02 1983-08-30 Children's Hospital Medical Center Cutaneous methods of measuring body substances
JPS56139607U (en) * 1980-03-24 1981-10-22

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 95, no. 14, 5 octobre 1981, pages 358-359, no. 121024f, Columbus, Ohio, USA; L.R. SEHGAL et al.: "Control of methemoglobin formation in stroma-free hemoglobin solutions" & J. SURG. RES. 1981, 31(1), 13-17 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0185404A1 (en) * 1984-11-09 1986-06-25 Euro-Trol B.V. Stroma-free hemoglobin solution, process for the preparation thereof and its application
EP0615747A1 (en) * 1993-03-18 1994-09-21 Terumo Kabushiki Kaisha Hemoglobin-encapsulating liposome and method for making the same
US5688526A (en) * 1993-03-18 1997-11-18 Terumo Kabushiki Kaisha Hemoglobin-encapsulating liposome and method for making the same
US5674528A (en) * 1994-06-15 1997-10-07 Terumo Kabushiki Kaisha Hemoglobin-encapsulated liposome

Also Published As

Publication number Publication date
US4485174A (en) 1984-11-27
EP0158684B1 (en) 1989-01-25
JPH0312706B2 (en) 1991-02-20
JPS60231166A (en) 1985-11-16

Similar Documents

Publication Publication Date Title
EP0158684B1 (en) Hemoglobin-based blood gas control
EP0465510B1 (en) A stable hemoglobin reference solution
Seakins et al. Erythrocyte Hb-S concentration An important factor in the low oxygen affinity of blood in sickle cell anemia
De Furia et al. The effects of cyanate in vitro on red blood cell metabolism and function in sickle cell anemia
US3973913A (en) Blood control standard
Bunn et al. Hemoglobin function in stored blood
US4711852A (en) Control for blood gas analyzers and hemoglobin analysis
US4126575A (en) Blood control standard
Duhm et al. Complete restoration of oxygen transport function and 2, 3‐diphosphoglycerate concentration in stored blood
US4551427A (en) Process and reagent for the determination of blood glucose in haemolysed whole blood
Sasakawa et al. Physical and chemical changes of ACD-preserved blood: a comparison of blood in glass bottles and plastic bags
US5558985A (en) Stable hemoglobin reference solution
Thompson et al. Rat liver cytoplasmic glucose-6-phosphate dehydrogenase. Steady-state kinetic properties and circular dichroism
CA1225911A (en) Hemoglobin-based blood gas control
US3963578A (en) Stabilization of phosphoenol pyruvate carboxylase
CA1079615A (en) Composition for the enzymic determination of glucose
EP0185404B1 (en) Stroma-free hemoglobin solution, process for the preparation thereof and its application
Blume et al. On the molecular basis of pyruvate kinase deficiency
Weik et al. Cell and mitochondria respiration of Naegleria fowleri
McLean et al. The influence of the metabolic state and of the medium on carbon dioxide fixation by Serratia marcescens
Magnani et al. Redox and energetic state of red blood cells in G6PD deficiency, heterozygous β-thalassemia and the combination of both
JP2001061498A (en) Reduced coenzyme solution
GERARD Influence of the redox state of glutathione upon pyruvate kinase in the intact erythrocyte
Versmold et al. Oxygen affinity of hemoglobins F and A partially oxidized to methemoglobin: Influence of 2, 3-diphosphoglycerate
KR20040095275A (en) Reagent for measuring alanine aminotransferase activity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): DE FR GB IT

17P Request for examination filed

Effective date: 19860411

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FISHER SCIENTIFIC COMPANY

17Q First examination report despatched

Effective date: 19880427

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

ITF It: translation for a ep patent filed
AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE FR GB IT

REF Corresponds to:

Ref document number: 3476462

Country of ref document: DE

Date of ref document: 19890302

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
REG Reference to a national code

Ref country code: GB

Ref legal event code: 732

ITPR It: changes in ownership of a european patent

Owner name: CESSIONE;INIZIATIVE MARITTIME 1991 S.R.L.

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Ref country code: FR

Ref legal event code: CD

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19930316

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19930322

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19930630

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19940416

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19940416

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19941229

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19960702